Praluent, Repatha: FDA guinea pigs to market trailblazers
This article was originally published in Scrip
Executive Summary
Sanofi's and Regeneron Pharmaceuticals' Praluent (alirocumab) and Amgen's Repatha (evolocumab) not only are the guinea pigs for how the FDA will handle the first proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor applications, but the drugs also are expected to be trailblazers in the marketplace for what's coming behind them – notably Pfizer's bococizumab, which is catching up fast to the two leaders.